Taselisib
Taselisib - 5mg is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Sign up to be the first to know when this product is in stock
Taselisib has a dual mechanism of action, both blocking kinase signaling and inducing down-regulation of the mutant p110alpha protein level in a dose-dependent and time-dependent manner. The taselisib-induced degradation of mutant p110a protein is ubiquitin-mediated and proteasome-dependent.
| Product Name | Taselisib |
| Synonyms | |
| CAS Number | 1282512-48-4 |
| Related CAS | |
| Molecular Formula | C24H28N8O2 |
| Molecular Weight | 460.542 |
| SMILES | CC(C)N1N=C(C)N=C1C1=CN2CCOC3=CC(=CC=C3C2=N1)C1=CN(N=C1)C(C)(C)C(N)=O |
| Purity (HPLC) | >= 95% |
| Physical Appearance | White solid |
| Solubility | DMSO, DMF |
| Shipping Conditions | Room Temperature |
| Storage Conditions | Refrigerated |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D.,Qin, J.-J., Protein degradation technology: a strategic paradigm shift in drug discovery. Journal of Hematology & Oncology 2021, 14, 138.Friedman, L., Edgar, K., Song, K., Schmidt, S., Kirkpatrick, D., Phu, L., Nannini, M., Hong, R., Cheng, E., Crocker, L., Young, A.,Sampath, D., Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Research 2017, 77, S6-04-S6-04.
Documents
Datasheet COA MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.
